CBER “Best Practices” Must Be Preserved In Reorg, Mass Bio Tells McClellan

The Center for Biologics Evaluation & Research ad review team should be transferred to the drug center as part of FDA's reorganization plan, the Massachusetts Biotech Council told Commissioner McClellan